Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
43.79
-0.48 (-1.08%)
At close: May 14, 2025, 3:59 PM
45.18
3.17%
After-hours: May 14, 2025, 06:13 PM EDT
Protagonist Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 |
|---|---|
| Development Services Revenue | 15.3M |
| Development Services Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.74M | 8.95M | 10.16M | 8.55M | 14.09M | 8.05M | 7.66M | 9.17M | 8.61M | 6.63M | 6.9M | 7.69M | 10.52M | 7.26M | 7.26M | 6.71M | 5.96M | 4.99M | 4.89M | 4.18M | 4.58M | 4.11M | 4.01M | 3.86M | 3.76M | 3.52M | 3.36M | 3.18M | 3.64M | 3.07M | 2.59M | 3.12M | 2.99M | 2.57M | 1.58M | 1.4M | 1.42M | 808K | 863K | 786K | 506K |
| Selling, General, and Administrative Revenue Growth | +31.09% | -11.85% | +18.83% | -39.33% | +74.99% | +5.09% | -16.46% | +6.59% | +29.75% | -3.90% | -10.27% | -26.86% | +44.83% | +0.06% | +8.06% | +12.57% | +19.44% | +2.11% | +17.09% | -8.72% | +11.42% | +2.29% | +3.93% | +2.63% | +7.02% | +4.64% | +5.76% | -12.74% | +18.59% | +18.43% | -17.00% | +4.45% | +16.20% | +63.22% | +13.05% | -1.41% | +75.12% | -6.37% | +9.80% | +55.34% | n/a |
| Research and Development Revenue | 35.89M | 34.9M | 35.97M | 33.52M | 33.73M | 28.9M | 30.66M | 33.18M | 27.42M | 29.88M | 25.4M | 34.61M | 36.32M | 38.37M | 36.96M | 26.43M | 24.25M | 19.49M | 15.99M | 20.26M | 18.77M | 15.91M | 17.29M | 19.36M | 12.44M | 14.25M | 12.14M | 17.73M | 15.37M | 11.72M | 11.17M | 12.01M | 11.28M | 8.82M | 5.56M | 5.7M | 5.63M | 4.19M | 3.16M | 2.3M | 2.18M |
| Research and Development Revenue Growth | +2.83% | -2.96% | +7.31% | -0.63% | +16.73% | -5.76% | -7.59% | +21.03% | -8.26% | +17.64% | -26.61% | -4.70% | -5.36% | +3.83% | +39.82% | +9.02% | +24.42% | +21.83% | -21.04% | +7.93% | +17.96% | -7.99% | -10.65% | +55.54% | -12.66% | +17.32% | -31.52% | +15.40% | +31.08% | +4.98% | -6.99% | +6.43% | +27.87% | +58.66% | -2.37% | +1.26% | +34.15% | +32.77% | +37.48% | +5.22% | n/a |